H.R. 107 · 116th Congress

To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.

Stage
In committee
Introduced
2019-01-03
Latest action
2019-01-25 · Referred to the Subcommittee on Health.

Summary

This bill terminates certain limitations regarding drug rebates under Medicaid. Currently, the maximum rebate that drug manufacturers must pay under Medicaid for single-source and innovator multiple-source drugs is 100% of the average manufacturer price of the drug. The bill specifies that this limitation only applies to rebate periods that begin before January 1, 2020.